While SII manufactures Molnupiravir, Biological-E. will manufacture CORBEVAX (File)
India gets a new Anti-viral drug Molnupiravir for Emergency use, CORBEVAX vaccine is the third Indian vaccine making it a hat-trick.
New Delhi: The country's proud and exemplary strides on the vaccine manufacturing front continue unabated.
The new Anti-viral drug Molnupiravir will be now available "for restricted use in emergency situations," tweeted Union Health Minister Dr Mansukh Mandaviya.
"Congratulations India. Further strengthening the fight against COVID-19, CDSCO, in Ministry of HFW_INDIA has given 3 approvals in a single day for: – CORBEVAX vaccine – COVOVAX vaccine, – Anti-viral drug Molnupiravir," he wrote.
The Minister said, "Molnupiravir, an antiviral drug, will now be manufactured in the country by 13 companies for restricted use under emergency situations for treatment of adult patients with COVID-19 and who have a high risk of progression of the disease."
On the Nanoparticle Vaccine COVOVAX, he said, Pune-based firm Serum Institute of India will manufacture the vaccine.
"PM @NarendraModi Ji has led the battle against #COVID19 from the front. All these approvals will further strengthen the global fight against the pandemic. Our Pharma Industries are asset for the entire world," he wrote on the microblogging site.
He also tweeted to declare that 'CORBEVAX vaccine' will be India's 1st indigenously developed RBD protein sub-unit vaccine against COVID-19. Hyderabad-based firm Biological-E. will manufacture the vaccine. "It's a hat-trick! It's now the 3rd vaccine developed in India," he said.
Leave a Comment